US › Healthcare

Senti Biosciences Inc (SNTI)

US · Healthcare · Biotechnology

$0.31+0.55%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$17,000

Net profit

$-12.8M

EPS

$-0.41

EPS estimate

$-0.33

Net margin

-75,000.0%

EPS came in at -0.41 against a street estimate of -0.33 — a miss of 24.2%.

Key statistics

Market cap

$9.5M

Forward P/E

0.0

P/B

5.45

Book value

$-0.11

EPS (TTM)

$-1.69

52-week high

$2.55

52-week low

$0.29

50-day MA

$0.49

200-day MA

$0.93

Beta

2.12

Analyst view

Analysts rate Senti Biosciences Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $13.50.

Shareholding

Insiders

47.91%

Institutions

19.00%

Largest institutional holders

Fund	Stake
NEA Management Company, LLC	12.12%
Nantahala Capital Management, LLC	2.85%
Geode Capital Management, LLC	0.66%
Citadel Advisors Llc	0.34%
Menlo Ventures Management, L.P.	0.11%
BlackRock Inc	0.08%
XTX Topco Ltd	0.06%
Northern Trust Corp	0.05%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Senti Biosciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.